BioGroup - Having done the cashflows
We have updated our analysis post the Q2 numbers, which has raised some potential trading opportunities across the capital structure. We lean on our extensive analysis of Cerba to inform us on our market expectations for BioGroup. Acknowledging that BioGroup has a different leverage starting point, enabling management to have some flexibility to further improve shareholder value. As we explore these options and overall French tariff expectations, we form our ultimate investment decision.